India is stepping into a new era of genomic innovation, and at the heart of this transformation is a powerful collaboration between two scientific giants CSIR–Institute of Genomics and Integrative Biology (CSIR-IGIB) and the Serum Institute of India Pvt. Ltd. (SIIPL). Their partnership marks a defining moment in the country’s pursuit of accessible, high-precision gene therapies.
The collaboration centers on enFnCas9, an engineered high-fidelity CRISPR-Cas9 platform developed by IGIB. This indigenous technology, admired for its accuracy and efficiency, has the potential to reshape how India confronts complex genetic diseases. Among its most urgent applications is sickle cell disease, a debilitating condition that disproportionately affects tribal communities in central and eastern India. For decades, these populations have carried the burden of limited treatment options, high morbidity, and shortened life expectancy.
By licensing enFnCas9 to the world’s largest vaccine manufacturer, the collaboration takes India closer to affordable, large-scale gene-editing solutions. The Serum Institute brings unmatched capacity in manufacturing and global deployment, ensuring that cutting-edge science does not remain confined to laboratories but reaches real people in real communities. With applications in both ex vivo and in vivo therapies, the partnership promises long-term, sustainable benefits.
CSIR-IGIB’s legacy in genomics is formidable. From sequencing the Indian genome to creating FELUDA, the country’s first CRISPR-based COVID-19 diagnostic, the institute has consistently led from the front. The enFnCas9 platform adds another milestone, positioning India as not just a participant but a leader in global CRISPR research.
Together, IGIB and the Serum Institute are charting a future where precision medicine is not a privilege, but a right.. accessible, affordable, and designed for India’s most vulnerable communities.
